Table 2. Treatment-related adverse events during the first induction period.

	Nivolumab followed by ipilimumab (n=68)			Ipilimumab followed by nivolumab (n=70)
	Grade 1–2	Grade 3	Grade 4	Grade 1–2	Grade 3	Grade 4
Pruritus	9 (13%)	0	0	23 (33%)	0	0
Rash	11 (16%)	0	0	15 (21%)	1 (1%)	0
Rash (maculopapular)	5 (7%)	0	0	9 (13%)	0	0
Fatigue	26 (38%)	0	0	24 (34%)	1 (1%)	0
Chills	3 (4%)	0	0	9 (13%)	0	0
Diarrhoea	8 (12%)	0	0	23 (33%)	1 (1%)	0
Nausea	7 (10%)	0	0	11 (16%)	2 (3%)	0
Colitis	0	0	0	3 (4%)	9 (13%)	0
Autoimmune colitis	0	0	0	0	1 (1%)	0
Diarrhoea (haemorrhagic)	0	0	0	0	1 (1%)	0
Increased ALT	4 (6%)	0	0	7 (10%)	1 (1%)	0
Increased AST	4 (6%)	0	0	7 (10%)	0	0
Increased lipase	1 (1%)	1 (1%)	0	7 (10%)	1 (1%)	0
Decreased neutrophil count	1 (1%)	0	0	0	0	1 (1%)
Decreased white blood cell count	1 (1%)	0	0	0	1 (1%)	0
Muscular weakness	2 (3%)	0	0	1 (1%)	1 (1%)	0
Headache	3 (4%)	1 (2%)	0	3 (4%)	0	0
Demyelinating polyneuropathy	0	0	1 (2%)	0	0	0
Myasthenia gravis	0	0	1 (2%)	0	0	0
Dyspnoea	4 (6%)	1 (1%)	0	1 (1%)	0	0
Pneumonitis	1 (1%)	1 (1%)	0	0	0	0
Macular oedema	2 (3%)	0	0	0	1 (1%)	0
Mental status changes	0	0	0	0	1 (1%)	0
Renal failure	0	0	0	0	1 (1%)	0

Data are n (%). ALT=alanine aminotransferase. AST=aspartate aminotransferase. No treatment-related deaths were recorded.